GlassScriptPhysician profile
Danielle M Vargas
NPI 1740775071
$2,725.66
in general payments reported to CMS, 2019-2025
18 companies · $961 in 2025
The $961 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $168 · 2022: $125 · 2023: $600 · 2024: $871 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,432.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $533.42 | 2021-2025 | Arexvy, Bexsero, Pediarix |
| Gilead Sciences, INC. | $243.45 | 2024-2025 | Yeztugo, Epclusa |
| Abbvie INC. | $225.93 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $152.03 | 2024-2025 | Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $147.27 | 2021-2022 | |
| Novo Nordisk INC | $138.13 | 2023-2025 | Wegovy |
| Antares Pharma, INC. | $129.32 | 2024 | Xyosted |
| Phathom Pharmaceuticals, INC. | $127.75 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.88 | 2025 | Xifaxan |
| Abbott Laboratories | $121.37 | 2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $121.19 | 2025 | Korlym |
| Amgen INC. | $120.39 | 2024 | Otezla |
| Astrazeneca Pharmaceuticals LP | $120.25 | 2025 | Lokelma |
| Kowa Pharmaceuticals America, INC. | $120.25 | 2025 | Zoryve |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $116.83 | 2023 | Veozah |
| Janssen Pharmaceuticals, INC | $33.20 | 2025 | Invega Sustenna, Invega Trinza |
| Hologic Sales and Service, LLC | $25.00 | 2023 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Vargas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.